JADE DARE trial met co-primary and key secondary endpoints and demonstrated a safety profile consistent with previous studies for moderate to severe atopic dermatitis
Opaganib, a leading novel small molecule investigational oral pill in development for Covid-19, is a unique host targeted, dual antiviral and anti-inflammatory drug that acts on the cause and effect of the disease
According to IQVIA sales data for the 12 month period ending April 2021, the Ofev Capsules, 100 mg and 150 mg market achieved annual sales of approximately US $1.6 billion
Natco has withdrawn its application filed with the Indian Patent Office, seeking Compulsory License against Lilly for Baricitinib for Covid-19 in India
The agreement will help ensure wider reach and access to patients in India
Baricitinib is used in combination with remdesivir for the treatment of suspected or laboratory confirmed COVID-19
The company will be requesting a Compulsory License based on emergency use and in light of the grave and serious public health emergency across India due to the Pandemic
The approval is for Ibrutinib tablets 560 mg, 420 mg, 280 mg and 140 mg strengths
Zydus was the first ANDA applicant to submit a substantially complete ANDA with a paragraph IV certification for Ibrutinib Capsules, 70 mg.
The receipt of this permission paves way for the launch of Osimertinib 40mg/80mg film coated tablets in India.
Subscribe To Our Newsletter & Stay Updated
